Award
InterMed Discovery of Dortmund, Germany, which specialises in discovering drugs from natural sources, has announced that it has received an award from the Michael J. Fox Foundation to advance the development of IMD-026259, a treatment to prevent neuro-degeneration in Parkinson’s disease.
IMD’s naturally based product candidate IMD-026259 inhibits hypoxia inducible factor-1 (HIF-1), inhibiting the process of oxidative stress, which is the root cause of the loss of dopamine-producing neurons that causes Parkinson’s diseases. The compound has demonstrated potent neuro-protective capabilities in biological models of the disease.
Philipp Wabnitz, Head Pharmacology at InterMed, said this is a novel approach to treating Parkinson’s disease. The funds will enable the company to further substantiate preclinical proof of principle.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
